Literature DB >> 17251298

Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.

Junji Shibata1, Kazuhisa Yoshimura, Akiko Honda, Atsushi Koito, Toshio Murakami, Shuzo Matsushita.   

Abstract

KD-247, a humanized monoclonal antibody to an epitope of gp120-V3 tip, has potent cross-neutralizing activity against subtype B primary human immunodeficiency virus type 1 (HIV-1) isolates. To assess how KD-247 escape mutants can be generated, we induced escape variants by exposing bulked primary R5 virus, MOKW, to increasing concentrations of KD-247 in vitro. In the presence of relatively low concentrations of KD-247, viruses with two amino acid mutations (R166K/D167N) in V2 expanded, and under high KD-247 pressure, a V3 tip substitution (P313L) emerged in addition to the V2 mutations. However, a virus with a V2 175P mutation dominated during passaging in the absence of KD-247. Using domain swapping analysis, we demonstrated that the V2 mutations and the P313L mutation in V3 contribute to partial and complete resistance phenotypes against KD-247, respectively. To identify the V2 mutation responsible for the resistance to KD-247, we constructed pseudoviruses with single or double amino acid mutations in V2 and measured their sensitivity to neutralization. Interestingly, the neutralization phenotypes were switched, so that amino acid residue 175 (Pro or Leu) located in the center of V2 was exchanged, indicating that the amino acid at position 175 has a crucial role, dramatically changing the Env oligomeric state on the membrane surface and affecting the neutralization phenotype against not only anti-V3 antibody but also recombinant soluble CD4. These data suggested that HIV-1 can escape from anti-V3 antibody attack by changing the conformation of the functional envelope oligomer by acquiring mutations in the V2 region in environments with relatively low antibody concentrations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17251298      PMCID: PMC1866102          DOI: 10.1128/JVI.01544-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  68 in total

1.  The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.

Authors:  Abraham Pinter; William J Honnen; Paul D'Agostino; Miroslaw K Gorny; Susan Zolla-Pazner; Samuel C Kayman
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

2.  Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.

Authors:  Chavdar Krachmarov; Abraham Pinter; William J Honnen; Miroslaw K Gorny; Phillipe N Nyambi; Susan Zolla-Pazner; Samuel C Kayman
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations.

Authors:  C Pastore; R Nedellec; A Ramos; S Pontow; L Ratner; D E Mosier
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

4.  Generation of high-affinity antibody against T cell-dependent antigen in the Ganp gene-transgenic mouse.

Authors:  Nobuo Sakaguchi; Tetsuya Kimura; Shuzo Matsushita; Satoru Fujimura; Junji Shibata; Masatake Araki; Tamami Sakamoto; Chiemi Minoda; Kazuhiko Kuwahara
Journal:  J Immunol       Date:  2005-04-15       Impact factor: 5.422

5.  Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses.

Authors:  Steven G Deeks; Becky Schweighardt; Terri Wrin; Justin Galovich; Rebecca Hoh; Elizabeth Sinclair; Peter Hunt; Joseph M McCune; Jeffrey N Martin; Christos J Petropoulos; Frederick M Hecht
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

6.  Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1.

Authors:  C P Krachmarov; W J Honnen; S C Kayman; M K Gorny; S Zolla-Pazner; Abraham Pinter
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

7.  Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.

Authors:  Alexandra Trkola; Herbert Kuster; Peter Rusert; Beda Joos; Marek Fischer; Christine Leemann; Amapola Manrique; Michael Huber; Manuela Rehr; Annette Oxenius; Rainer Weber; Gabriela Stiegler; Brigitta Vcelar; Hermann Katinger; Leonardo Aceto; Huldrych F Günthard
Journal:  Nat Med       Date:  2005-05-08       Impact factor: 53.440

8.  Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif.

Authors:  Yasuyuki Eda; Mari Takizawa; Toshio Murakami; Hiroaki Maeda; Kazuhiko Kimachi; Hiroshi Yonemura; Satoshi Koyanagi; Kouichi Shiosaki; Hirofumi Higuchi; Keiichi Makizumi; Toshihiro Nakashima; Kiyoshi Osatomi; Sachio Tokiyoshi; Shuzo Matsushita; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

9.  Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection.

Authors:  Yasuyuki Eda; Toshio Murakami; Yasushi Ami; Tadashi Nakasone; Mari Takizawa; Kenji Someya; Masahiko Kaizu; Yasuyuki Izumi; Naoto Yoshino; Shuzo Matsushita; Hirofumi Higuchi; Hajime Matsui; Katsuaki Shinohara; Hiroaki Takeuchi; Yoshio Koyanagi; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

10.  Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.

Authors:  R Wyatt; J Moore; M Accola; E Desjardin; J Robinson; J Sodroski
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

View more
  14 in total

1.  Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds.

Authors:  Kazuhisa Yoshimura; Shigeyoshi Harada; Junji Shibata; Makiko Hatada; Yuko Yamada; Chihiro Ochiai; Hirokazu Tamamura; Shuzo Matsushita
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

2.  Characterization of structural features and diversity of variable-region determinants of related quaternary epitopes recognized by human and rhesus macaque monoclonal antibodies possessing unusually potent neutralizing activities.

Authors:  Chavdar Krachmarov; Zhong Lai; William J Honnen; Aidy Salomon; Miroslaw K Gorny; Susan Zolla-Pazner; James Robinson; Abraham Pinter
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

Review 3.  The HIV-1 env protein: a coat of many colors.

Authors:  Kathryn Twigg Arrildt; Sarah Beth Joseph; Ronald Swanstrom
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

4.  Impact of antiretroviral pressure on selection of primary human immunodeficiency virus type 1 envelope sequences in vitro.

Authors:  Shigeyoshi Harada; Kazuhisa Yoshimura; Aki Yamaguchi; Samatchaya Boonchawalit; Keisuke Yusa; Shuzo Matsushita
Journal:  J Gen Virol       Date:  2013-01-03       Impact factor: 3.891

5.  Evolution of the HIV-1 env gene in the Rag2-/- gammaC-/- humanized mouse model.

Authors:  William L Ince; Liguo Zhang; Qi Jiang; Kathryn Arrildt; Lishan Su; Ronald Swanstrom
Journal:  J Virol       Date:  2009-12-30       Impact factor: 5.103

6.  Maternal neutralizing antibodies against a CRF01_AE primary isolate are associated with a low rate of intrapartum HIV-1 transmission.

Authors:  Tanawan Samleerat; Suzie Thenin; Gonzague Jourdain; Nicole Ngo-Giang-Huong; Alain Moreau; Pranee Leechanachai; Jirapan Ithisuknanth; Karin Pagdi; Pornpun Wannarit; Suraphan Sangsawang; Marc Lallemant; Francis Barin; Martine Braibant
Journal:  Virology       Date:  2009-03-20       Impact factor: 3.616

7.  Structural dynamics of HIV-1 envelope Gp120 outer domain with V3 loop.

Authors:  Masaru Yokoyama; Satoshi Naganawa; Kazuhisa Yoshimura; Shuzo Matsushita; Hironori Sato
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

8.  Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies.

Authors:  Peter Rusert; Anders Krarup; Carsten Magnus; Oliver F Brandenberg; Jacqueline Weber; Anna-Katharina Ehlert; Roland R Regoes; Huldrych F Günthard; Alexandra Trkola
Journal:  J Exp Med       Date:  2011-06-06       Impact factor: 14.307

9.  Differences in the Selection Bottleneck between Modes of Sexual Transmission Influence the Genetic Composition of the HIV-1 Founder Virus.

Authors:  Damien C Tully; Colin B Ogilvie; Rebecca E Batorsky; David J Bean; Karen A Power; Musie Ghebremichael; Hunter E Bedard; Adrianne D Gladden; Aaron M Seese; Molly A Amero; Kimberly Lane; Graham McGrath; Suzane B Bazner; Jake Tinsley; Niall J Lennon; Matthew R Henn; Zabrina L Brumme; Philip J Norris; Eric S Rosenberg; Kenneth H Mayer; Heiko Jessen; Sergei L Kosakovsky Pond; Bruce D Walker; Marcus Altfeld; Jonathan M Carlson; Todd M Allen
Journal:  PLoS Pathog       Date:  2016-05-10       Impact factor: 6.823

10.  Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation.

Authors:  Oliver F Brandenberg; Peter Rusert; Carsten Magnus; Jacqueline Weber; Jürg Böni; Huldrych F Günthard; Roland R Regoes; Alexandra Trkola
Journal:  Retrovirology       Date:  2014-09-25       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.